LED Medical Forms Partnership with BC Cancer Agency and Genome BC for Oral Cancer Risk-Assessment Test

LED Medical Diagnostics (TSXV:LMD,OTCQX:LEDIF,FWB:LME) has signed an agreement with the BC Cancer Agency for a collaborative relationship with Genome British Columbia to create and commercialize a progression-risk assessment test for oral cancer.
As quoted in the press release:

The project, titled “Development of an actionable molecular test for risk assessment of oral precancers,” is funded by the Genome BC Strategic Opportunities Fund, and is designed to leverage research funded by the National Institute of Health and the Terry Fox Research Institute. Dr. Catherine Poh, project Team Leader, is an Associate Professor, Faculty of Dentistry, University of British Columbia, and a Senior Clinician Scientist of the British Columbia Oral Cancer Prevention Program at the BC Cancer Agency.

Click here to read the LED Medical Diagnostics (TSXV:LMD,OTCQX:LEDIF,FWB:LME) press release